Advertisement
Perspective

Perspective Perspectives are commissioned from an expert and discuss the clinical practice or public health implications of a published study. The original publication must be freely available online.

See all article types »

Open Clinical Trial Data for All? A View from Regulators

  • Hans-Georg Eichler mail,

    hans-georg.eichler@ema.europa.eu

    Affiliation: European Medicines Agency (EMA), London, United Kingdom

    X
  • Eric Abadie,

    Affiliations: European Medicines Agency (EMA), London, United Kingdom, Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) Saint-Denis, France

    X
  • Alasdair Breckenridge,

    Affiliation: Medicines and Healthcare products Regulatory Agency (MHRA), London, United Kingdom

    X
  • Hubert Leufkens,

    Affiliations: European Medicines Agency (EMA), London, United Kingdom, Medicines Evaluation Board (CBG-MEB), Den Haag, The Netherlands

    X
  • Guido Rasi

    Affiliation: European Medicines Agency (EMA), London, United Kingdom

    X
  • Published: April 10, 2012
  • DOI: 10.1371/journal.pmed.1001202

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.

Linked Articles

The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience

Peter Doshi, Tom Jefferson, Chris Del Mar
Policy Forum | published 10 Apr 2012 | PLOS Medicine
doi:10.1371/journal.pmed.1001201